Goldman Sachs
|
|
|
|
|
Investors joining hedge fund club get burned
NEW YORK (Reuters) - Two years ago, investors scrambled to snap up shares in elite hedge fund firms, eager for a piece of the lucrative action. Full Article
UPDATE 2-Wyeth says biotech deals likely despite hardships
(Clarifies timeframe for Prevnar 13 filing; updates shares) Full Article
FACTBOX: The Fed's evolving liquidity toolkit
(Reuters) - The U.S. Federal Reserve said on Wednesday it was expanding and tweaking the parameters of its money market credit facility to include a wider array of investors and keep the program viable even with money market yields at rock-bottom levels. Full Article
Stocks in biggest fall in a month on jobs and tech
NEW YORK (Reuters) - Stocks suffered their worst decline in more than a month on Wednesday after a grim private-sector jobs report coupled with a revenue warning from top chip maker Intel Corp revived deep concerns about the economy. Full Article
US STOCKS-Wall St in biggest fall in a month on jobs, tech
* Dow off 2.7 pct, S&P 500 off 3 pct, Nasdaq off 3.2 pct Full Article
US STOCKS-Wall St in biggest fall in a month on jobs, tech
* Dow off 2.7 pct, S&P 500 off 3 pct, Nasdaq off 3.2 pct Full Article
Nabors Industries sells $1.125 bln in 10-yr notes - IFR
NEW YORK, Jan 7 (Reuters) - Nabors Industries on Wednesday sold $1.125 billion in 10-year notes in the 144a private placement market, according to IFR. Full Article
Blue Tulip files for Chapter 11, seeks to liquidate
Jan 7 (Reuters) - Blue Tulip Corp, a retailer of gifts and entertainment products, filed for Chapter 11 bankruptcy in a Delaware court on Monday, saying the economic downturn had severely hurt the company's performance and its ability to satisfy debt obligations. Full Article
US STOCKS-Jobs gloom, weak techs push Wall St lower
* Dow off 2.8 pct, S&P 500 off 3 pct, Nasdaq off 3.3 pct Full Article
UPDATE 1-Merck CEO faults company's record in 2008
NEW YORK, Jan 7 (Reuters) - The chief executive of Merck & Co Inc said on Wednesday several setbacks last year were partly due to poor company execution, including failure to win U.S. approval for its Cordaptive cholesterol pill or approval to sell its Gardasil cervical cancer vaccine to older girls and women. Full Article
